Trial · NCT06291831
A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.
NCT06291831, Completed, Pfizer; results first posted 2025-08-19
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain. Trials, record NCT06291831. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06291831
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.
- NCT number
- NCT06291831
- Status
- Completed
- Enrollment
- 3,011 participants, actual
- Lead sponsor
- Pfizer
- Conditions
- COVID-19
- Interventions
- nirmatrelvir, ritonavir, Controls
- First posted
- 2024-03-04
- Last updated
- 2025-08-19
- Results first posted
- 2025-08-19
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Classified Based on Education | Baseline; from available retrospective data evaluated during 2 months of this study | Baseline was defined as one year before the index date. Index date was Paxlovid prescription written date or dispense date; if neither of them were available, the COVID-19 diagnosis date was used as the index date. |
| Primary | Number of Participants Classified Based on Employment Status | Baseline; from available retrospective data evaluated during 2 months of this study | Baseline was defined as one year before the index date. Index date was Paxlovid prescription written date or dispense date; if neither of them were available, the COVID-19 diagnosis date was used as the index date. |
| Primary | Height | Baseline; from available retrospective data evaluated during 2 months of this study | Baseline was defined as one year before the index date. Index date was Paxlovid prescription written date or dispense date; if neither of them were available, the COVID-19 diagnosis date was used as the index date. |
| Primary | Weight | Baseline; from available retrospective data evaluated during 2 months of this study | Baseline was defined as one year before the index date. Index date was Paxlovid prescription written date or dispense date; if neither of them were available, the COVID-19 diagnosis date was used as the index date. |
| Primary | Body Mass Index (BMI) | Baseline; from available retrospective data evaluated during 2 months of this study | Baseline was defined as one year before the index date. Index date was Paxlovid prescription written date or dispense date; if neither of them were available, the COVID-19 diagnosis date was used as the index date. |
| Primary | Number of Participants Classified Based on Smoking Status | Baseline; from available retrospective data evaluated during 2 months of this study | Baseline was defined as one year before the index date. Index date was Paxlovid prescription written date or dispense date; if neither of them were available, the COVID-19 diagnosis date was used as the index date. |
| Primary | Number of Participants With at Least 1 Pre-existing Comorbidities | Baseline; from available retrospective data evaluated during 2 months of this study | Pre-existing comorbidities included: asthma, emphysema, chronic obstructive pulmonary disease (COPD), hypertension, diabetes, obesity, cerebrovascular disease, neurological disease, chronic kidney disease, chronic liver disease, malignancy. Baseline was defined as one year before the index date. Index date was Paxlovid prescription written date or dispense date; if neither of them were available, the COVID-19 diagnosis date was used as the index date. |
| Primary | Number of Participants Who Took at Least 1 Concomitant Medications for Pre-existing Comorbidities | Baseline; from available retrospective data evaluated during 2 months of this study | Baseline was defined as one year before the index date. Index date was Paxlovid prescription written date or dispense date; if neither of them were available, the COVID-19 diagnosis date was used as the index date. |
| Primary | Number of Participants Who Used Antibiotics | Up to 24 months following COVID-19 diagnosis; from available retrospective data evaluated during 2 months of this study | |
| Secondary | Number of Participants With Hospitalization for Any Cause | Up to 24 months following COVID-19 diagnosis; from available retrospective data evaluated during 2 months of this study |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes17
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Classified Based on Education | Baseline; from available retrospective data evaluated during 2 months of this study | I-Seha EHR was used to retrieve the data in this study for evaluation of its objectives. Education information required for this outcome measure was not available in I-Seha EHR. Hence, there was no data that could be analyzed for this outcome measure. | ||
| PRIMARY | Number of Participants Classified Based on Employment Status | Baseline; from available retrospective data evaluated during 2 months of this study | I-Seha EHR was used to retrieve the data in this study for evaluation of its objectives. Employment status information required for this outcome measure was not available in I-Seha EHR. Hence, there was no data that could be analyzed for this outcome measure. | ||
| PRIMARY | Height | Baseline; from available retrospective data evaluated during 2 months of this study | I-Seha EHR was used to retrieve the data in this study for evaluation of its objectives. Height information required for this outcome measure was not available in I-Seha EHR. Hence, there was no data that could be analyzed for this outcome measure. | ||
| PRIMARY | Weight | Baseline; from available retrospective data evaluated during 2 months of this study | I-Seha EHR was used to retrieve the data in this study for evaluation of its objectives. Weight information required for this outcome measure was not available in I-Seha EHR. Hence, there was no data that could be analyzed for this outcome measure. | ||
| PRIMARY | Body Mass Index (BMI) | Baseline; from available retrospective data evaluated during 2 months of this study | Analysis population included all eligible participants whose data were included and observed in this study. BMI was extracted from records and method how it was collected originally was not known. | Kilogram over meter square (Kg/m^2) | MEDIAN |
| PRIMARY | Number of Participants Classified Based on Smoking Status | Baseline; from available retrospective data evaluated during 2 months of this study | I-Seha EHR was used to retrieve the data in this study for evaluation of its objectives. Smoking status information required for this outcome measure was not available in I-Seha EHR. Hence, there was no data that could be analyzed for this outcome measure. | ||
| PRIMARY | Number of Participants With at Least 1 Pre-existing Comorbidities | Baseline; from available retrospective data evaluated during 2 months of this study | Analysis population included all eligible participants whose data were included and observed in this study. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Who Took at Least 1 Concomitant Medications for Pre-existing Comorbidities | Baseline; from available retrospective data evaluated during 2 months of this study | I-Seha EHR was used to retrieve the data in this study for evaluation of its objectives. Concomitant medications for pre-existing comorbidities information required for this outcome measure was not available in I-Seha EHR. Hence, there was no data that could be analyzed for this outcome measure. | ||
| PRIMARY | Number of Participants Who Used Antibiotics | Up to 24 months following COVID-19 diagnosis; from available retrospective data evaluated during 2 months of this study | Analysis population included all eligible participants whose data were included and observed in this study. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Hospitalization for Any Cause | Up to 24 months following COVID-19 diagnosis; from available retrospective data evaluated during 2 months of this study | Analysis population included all eligible participants whose data were included and observed in this study. | Participants | COUNT_OF_PARTICIPANTS |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 outcomesResults by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Body Mass Index (BMI) | Treated With Paxlovid | 29 | Inter-Quartile Range 25 to 33 | Kilogram over meter square (Kg/m^2) | |
| Body Mass Index (BMI) | Not Treated With Paxlovid | 29 | Inter-Quartile Range 25 to 34 | Kilogram over meter square (Kg/m^2) | |
| Number of Participants With at Least 1 Pre-existing Comorbidities | Treated With Paxlovid | 1709 | Participants | ||
| Number of Participants With at Least 1 Pre-existing Comorbidities | Not Treated With Paxlovid | 920 | Participants | ||
| Number of Participants Who Used Antibiotics | Treated With Paxlovid | For any cause | 530 | Participants | |
| Number of Participants Who Used Antibiotics | Not Treated With Paxlovid | For any cause | 320 | Participants | |
| Number of Participants Who Used Antibiotics | Treated With Paxlovid | For COVID-19 | 118 | Participants | |
| Number of Participants Who Used Antibiotics | Not Treated With Paxlovid | For COVID-19 | 103 | Participants | |
| Number of Participants With Hospitalization for Any Cause | Treated With Paxlovid | 137 | Participants | ||
| Number of Participants With Hospitalization for Any Cause | Not Treated With Paxlovid | 123 | Participants |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treated With Paxlovid | 2,005 | |
| Overall Study | STARTED | Not Treated With Paxlovid | 1,006 | |
| Overall Study | COMPLETED | Treated With Paxlovid | 2,005 | |
| Overall Study | COMPLETED | Not Treated With Paxlovid | 1,006 | |
| Overall Study | NOT COMPLETED | Treated With Paxlovid | 0 | |
| Overall Study | NOT COMPLETED | Not Treated With Paxlovid | 0 |
Source ClinicalTrials.gov
Adverse events32
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Impaired sense of taste / Bitterness | General disorders | Treated With Paxlovid | 1,214 | 2,005 | |
| other | Impaired sense of taste / Bitterness | General disorders | Not Treated With Paxlovid | 0 | 0 | |
| other | Impaired sense of smell | General disorders | Treated With Paxlovid | 2 | 2,005 | |
| other | Impaired sense of smell | General disorders | Not Treated With Paxlovid | 0 | 0 | |
| other | Stomach/Abdominal pain | General disorders | Treated With Paxlovid | 47 | 2,005 | |
| other | Stomach/Abdominal pain | General disorders | Not Treated With Paxlovid | 0 | 0 | |
| other | Diarrhea | General disorders | Treated With Paxlovid | 365 | 2,005 | |
| other | Diarrhea | General disorders | Not Treated With Paxlovid | 0 | 0 | |
| other | Nausea/Vomiting | General disorders | Treated With Paxlovid | 44 | 2,005 | |
| other | Nausea/Vomiting | General disorders | Not Treated With Paxlovid | 0 | 0 |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treated With Paxlovid | 0 | 2,005 |
| Total, all-cause mortality | Not Treated With Paxlovid | 0 | 1,006 |
| Total, other adverse events | Treated With Paxlovid | 1,427 | 2,005 |
| Total, other adverse events | Not Treated With Paxlovid | 0 | 0 |
| Total, serious adverse events | Treated With Paxlovid | 0 | 2,005 |
| Total, serious adverse events | Not Treated With Paxlovid | 0 | 0 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41051660 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons7
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Emergency Room (ER) Visits for Any Cause | Trial comparisons |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Hospitalization for Any Cause | Trial comparisons |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants Who Used Invasive Mechanical Ventilation (IMV) | Trial comparisons |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Supplemental Oxygen Usage | Trial comparisons |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With at Least 1 Pre-existing Comorbidities | Trial comparisons |
| Treated With Paxlovid vs Not Treated With Paxlovid: deaths from any cause | Trial comparisons |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Intensive Care Unit (ICU) Admission for Any Cause | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06291831
GET https://conductscience.org/api/trials/v1/NCT06291831/results?page=2